| Date | Time | Source | Headline | Symbol | Company |
| 09/20/2024 | 6:53PM | Business Wire | Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt | NYSE:JNJ | Johnson and Johnson |
| 09/20/2024 | 4:19PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
| 09/20/2024 | 3:43PM | Business Wire | Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims | NYSE:JNJ | Johnson and Johnson |
| 09/19/2024 | 6:54PM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer | NYSE:JNJ | Johnson and Johnson |
| 09/17/2024 | 6:40AM | IH Market News | Microsoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with Amazon | NYSE:JNJ | Johnson and Johnson |
| 09/16/2024 | 2:50AM | PR Newswire (US) | Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer | NYSE:JNJ | Johnson and Johnson |
| 09/15/2024 | 2:30AM | PR Newswire (US) | New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer | NYSE:JNJ | Johnson and Johnson |
| 09/14/2024 | 9:45AM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer | NYSE:JNJ | Johnson and Johnson |
| 09/14/2024 | 3:10AM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer | NYSE:JNJ | Johnson and Johnson |
| 09/12/2024 | 4:44PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
| 09/12/2024 | 4:43PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
| 09/11/2024 | 6:22PM | PR Newswire (US) | TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease | NYSE:JNJ | Johnson and Johnson |
| 09/10/2024 | 5:15PM | PR Newswire (US) | Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw) | NYSE:JNJ | Johnson and Johnson |
| 09/10/2024 | 4:26PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
| 09/08/2024 | 1:47PM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer | NYSE:JNJ | Johnson and Johnson |
| 09/05/2024 | 4:30PM | Business Wire | Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results | NYSE:JNJ | Johnson and Johnson |
| 09/05/2024 | 6:11AM | IH Market News | Qualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual Listing | NYSE:JNJ | Johnson and Johnson |
| 09/03/2024 | 4:48PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
| 08/30/2024 | 3:51PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:JNJ | Johnson and Johnson |
| 08/29/2024 | 2:05PM | Edgar (US Regulatory) | Form N-PX - Annual Report of proxy voting record of management investment companies | NYSE:JNJ | Johnson and Johnson |
| 08/29/2024 | 8:00AM | PR Newswire (US) | Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis | NYSE:JNJ | Johnson and Johnson |
| 08/27/2024 | 8:00AM | PR Newswire (US) | Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress | NYSE:JNJ | Johnson and Johnson |
| 08/26/2024 | 4:26PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
| 08/26/2024 | 8:58AM | IH Market News | IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts | NYSE:JNJ | Johnson and Johnson |
| 08/26/2024 | 8:00AM | Business Wire | Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024 | NYSE:JNJ | Johnson and Johnson |
| 08/21/2024 | 8:12AM | IH Market News | Walmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest News | NYSE:JNJ | Johnson and Johnson |
| 08/20/2024 | 7:30AM | Business Wire | Johnson & Johnson to Acquire V-Wave | NYSE:JNJ | Johnson and Johnson |
| 08/20/2024 | 7:00AM | PR Newswire (US) | RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer | NYSE:JNJ | Johnson and Johnson |
| 08/15/2024 | 6:05AM | IH Market News | Google Forced to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova | NYSE:JNJ | Johnson and Johnson |
| 08/15/2024 | 6:05AM | IH Market News | Google Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys Kellanova | NYSE:JNJ | Johnson and Johnson |